Literature DB >> 1602914

Intracranial complications of mucormycosis: an experimental model and clinical review.

V K Anand1, G Alemar, J A Griswold.   

Abstract

The clinical course of patients with mucormycosis of the paranasal sinuses can be unpredictable and is often determined by intrinsic host factors. The degree to and mechanism(s) by which these factors influence a patient's ability to survive the disease are poorly understood. Extensions to orbital and intracranial structures occur in some patients with paranasal sinus mucormycosis despite aggressive treatment. Controversies persist over adequate antifungal regimen, the precise role of hyperbaric oxygenation, and the appropriate extent of surgical debridement. We have developed an alloxan-induced immunocompromised murine model of mucormycosis in mice. Deferoxamine iron chelation produced rhinocerebral mucormycosis in these animals when challenged intraethmoidally with Rhizopus spores. The implications of our experimental studies in the content of our clinical experience in managing patients with intracranial extensions of paranasal sinus mucormycosis are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602914     DOI: 10.1288/00005537-199206000-00011

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  9 in total

Review 1.  Pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

2.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 3.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

4.  Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model.

Authors:  D M Barratt; K Van Meter; P Asmar; T Nolan; C Trahan; L Garcia-Covarrubias; S E Metzinger
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 5.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Mucor Thrombus.

Authors:  E L Scharf; H J Cloft; E Wijdicks
Journal:  Neurocrit Care       Date:  2016-04       Impact factor: 3.210

7.  Rhinocerebral mucormycosis: An analysis of probable mode of spread and its implication in an early diagnosis and treatment.

Authors:  N S Kulkarni; A R Bhide; R S Wadia
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2005-04

Review 8.  Animal models of zygomycosis--Absidia, Rhizopus, Rhizomucor, and Cunninghamella.

Authors:  K Kamei
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

9.  Rhinocerebral mucormycosis in a 5-month heart transplant recipient.

Authors:  Gabriel Pedemonte-Sarrias; Juan Ramon Gras-Cabrerizo; Fernando Rodríguez-Álvarez; Joan Ramon Montserrat-Gili
Journal:  J Oral Maxillofac Pathol       Date:  2015 Sep-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.